Acrivon Therapeutics
Boston, US · Founded 2018 · 3 known investors
Find your way into Acrivon Therapeutics
1,082 people in our graph share verified history with the Acrivon Therapeutics team — schools, employers, funds. One of them is your warm intro.
Viswa Sankaranarayananunlockedknows Eric Devroe · together at The University of Texas at Austin (overlapped)
knows the team · via The University of Texas at Austin
×5knows the team · via Harvard University
×3knows the team · via Université Paris Cité
knows the team · via Amgen
knows the team · via MD Anderson Cancer Center
Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
Founders & leadership
Acrivon Therapeutics was founded in 2018 by Peter Blume-Jensen and Kristina Masson.
PB
Peter Blume-JensenCo-founder
KM
Kristina MassonCo-founder
EG
erick gamelininChief Development Officer (CDO)2024–2026Erick Gamelin is a biotech and oncology executive with three decades of experience in academic medicine, pharmaceutical development, and biotechnology. He previously served as CEO of Institut de Cancérologie de l'Ouest in France, led global oncology and immunology programs at major pharmaceutical companies resulting in multiple FDA and EMA approvals, and co-founded Acrivon Therapeutics, taking it public on NASDAQ in 2022.
ED
Eric DevroeinExecutiveEric Devroe served as Chief Operating Officer of Acrivon Therapeutics, overseeing operations, pipeline management, and companion diagnostics through the company's IPO. Previously, he founded Opsonix and Xione Therapeutics, held leadership roles in business development at MD Anderson Cancer Center's Institute for Applied Cancer Sciences and Metamark Genetics, and was a venture associate at Flagship Pioneering, with 20+ years of experience in biotech operations, fundraising, and translational science.
Board
MC
Marcin CzernikBoard director
SS
Sharon ShachamBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$115.5M disclosed across 2 rounds · 2021
▶$100MraisedNov 2021 · 13 investors · BiotechnologyRule 506(b)
▶$100MraisedNov 2021 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Peter Blume-JensenExecutive Officer, Director
- Sharon ShachamDirector
- Kristina MassonExecutive Officer, Director
- Derek DiRoccoDirector
- Marcin CzernikDirector
- Erick GamelinExecutive Officer
- Eric DevroeExecutive Officer
- Offering amount
- $100M
- Amount sold
- $100M
- First sale
- Nov 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
▶$15.5MraisedFeb 2021 · 2 investors · BiotechnologyRule 506(b)
▶$15.5MraisedFeb 2021 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Sharon ShachamDirector
- Peter Blume-JensenExecutive Officer, Director
- Kristina MassonExecutive Officer, Director
- Marcin CzernikDirector
- Eric DevroeExecutive Officer
- Offering amount
- $15.5M
- Amount sold
- $15.5M
- First sale
- Jan 2021
- Incorporated
- Corporation, Delaware, 2018
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Acrivon Therapeutics do?
- Acrivon is a clinical-stage oncology company developing precision medicine therapeutics for cancer treatment, using its proprietary AP3 proteomics platform to create companion diagnostics that match patients to drugs based on tumor-driving mechanisms.
- Who founded Acrivon Therapeutics?
- Acrivon Therapeutics was founded by Peter Blume-Jensen, Kristina Masson in 2018.
- Who are Acrivon Therapeutics's investors?
- Acrivon Therapeutics's investors include New Enterprise Associates (NEA), Pureos Bioventures, RA Capital.
- How much funding has Acrivon Therapeutics raised?
- Acrivon Therapeutics has disclosed $115.5M raised across 2 rounds.
- Where is Acrivon Therapeutics headquartered?
- Acrivon Therapeutics is headquartered in Boston, US.